The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Impact of novel therapies on real-world outcomes of patients with R/R MCL by ethnicity & TP53m
Tycel Phillips, MD, City of Hope, Duarte, CA, comments on the impact of novel therapies on real-world clinical outcomes of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), highlighting ethnic differences in response to initial chemoimmunotherapy and novel treatments. Dr Phillips notes that Hispanic patients, in particular, showed a favorable response to chemoimmunotherapy, even in the second-line setting. In contrast, Asian and Black patients showed an improvement in response parameters with novel treatments in the second-line setting. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
